Day: January 18, 2023

TORONTO and MINNEAPOLIS, Jan. 18, 2023 (GLOBE NEWSWIRE) — Ceridian HCM Holding Inc. (NYSE:CDAY) (TSX:CDAY), a global leader in human capital management (HCM) technology, announced today that it will release fourth quarter and full-year 2022 financial results after the close of regular market trading on Wednesday, February 8, 2023. The company will host a live webcast at 5:00 p.m. Eastern Time on February 8, 2023 to discuss the aforementioned financial results. The event can be accessed via direct registration link or through the Ceridian Investor Relations website. A replay and transcript will be available after the conclusion of the live event on the Ceridian Investor Relations website. About Ceridian Ceridian. Makes Work Life Better™. Ceridian is a global human capital management software company. Dayforce, its flagship...

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2023 OTCQX® Best 50, a ranking of the top-performing OTCQX companies in the prior calendar year. The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX Best Market, based on an equal weighting of one-year total return and average daily dollar volume growth. Companies in the 2023 OTCQX Best 50 were ranked based on their performance during the 2022 calendar year. “We congratulate the 2023 OTCQX Best 50 companies on being able to outperform their peers in a year of difficult market conditions,” said Jason Paltrowitz, OTC Markets Group EVP of Corporate Services. “This year’s roster represents the breadth of industries and geographies that contribute to the diverse range of OTCQX-traded...

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI–2620 for Alzheimer’s DiseaseFirst Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3 trial PI-2620 potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregated Tau Tau accumulation, a key Alzheimer’s disease pathology, correlates with cognitive impairmentLausanne, Switzerland, January 18, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its collaboration partner, Life Molecular Imaging (LMI), has imaged the first patient in ADvance, the pivotal Phase 3 trial of PI-2620, a Tau PET (positron emission tomography) imaging agent for AD (Alzheimer’s disease). PI-2620...

National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), resulting in millions of patients gaining access to the broad-spectrum, once daily antibiotic. “The addition of NUZYRA to China’s NRDL means millions of patients now benefit from increased accessibility to this life-saving therapy for serious community-acquired...

Vancouver, Jan. 18, 2023 (GLOBE NEWSWIRE) —As announced on 14 December 2022, Victory’s Exploration Team has completed an on-site geological program to finalize the location of drill holes, building upon its previously reported comprehensive effort to delineate significant lithium mineralization on the Smokey Lithium Property Drill hole locations have been selected to extend strong lithium mineralization intersected previously on the property in hole 09 within the area of interest outlined in detail in the Company’s press release dated 20 October 2022 The Company has now amended and submitted its drill permit application with the newly identified hole locations in this new area of interest contiguous with the southwest part of the original claim blockVANCOUVER, BC, CANADA (18 January 2023) – Victory Battery Metals (CSE:...

Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium (186Re) obisbemeda for the treatment of recurrent glioblastoma (GBM). This Phase 2b multi-center trial is designed to evaluate the safety, tolerability, distribution and efficacy of rhenium (186Re) obisbemeda infused directly into the tumor via convection-enhanced delivery catheters in patients with recurrent GBM progressing after conventional treatment. “In...